Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 276

1.

Venous thrombosis and conjugated equine estrogen in women without a uterus.

Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR.

Arch Intern Med. 2006 Apr 10;166(7):772-80.

PMID:
16606815
2.

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.

Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S.

Ann Intern Med. 2000 May 2;132(9):689-96.

PMID:
10787361
3.

Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.

McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS; Women's Health Initiative Mammogram Density Study Investigators.

J Natl Cancer Inst. 2005 Sep 21;97(18):1366-76.

PMID:
16174858
4.

Estrogen plus progestin and the risk of coronary heart disease.

Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators.

N Engl J Med. 2003 Aug 7;349(6):523-34.

5.

Estrogen plus progestin and risk of venous thrombosis.

Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR; Women's Health Initiative Investigators.

JAMA. 2004 Oct 6;292(13):1573-80.

PMID:
15467059
6.

Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative.

Hsia J, Criqui MH, Rodabough RJ, Langer RD, Resnick HE, Phillips LS, Allison M, Bonds DE, Masaki K, Caralis P, Kotchen JM; Women's Health Initiative Investigators.

Circulation. 2004 Feb 10;109(5):620-6.

7.

Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.

Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R; Women's Health Initiative Investigators.

Arch Intern Med. 2006 Feb 13;166(3):357-65. Erratum in: Arch Intern Med. 2006 Apr 10;166(7):759.

PMID:
16476878
8.

Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.

Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, David Curb J, Hendrix SL, Allan Hubbell F, Khandekar J, Lane DS, Lasser N, Lopez AM, Potter J, Ritenbaugh C.

Maturitas. 2006 Sep 20;55(2):103-15. Epub 2006 Jul 11.

PMID:
16815651
9.

Menopause and stroke and the effects of hormonal therapy.

Lobo RA.

Climacteric. 2007 Oct;10 Suppl 2:27-31. Review.

PMID:
17882669
10.

Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial.

Yasmeen S, Romano PS, Pettinger M, Johnson SR, Hubbell FA, Lane DS, Hendrix SL.

Obstet Gynecol. 2006 Aug;108(2):410-9.

PMID:
16880313
11.

Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.

Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL.

J Natl Cancer Inst. 2008 Apr 16;100(8):563-71. doi: 10.1093/jnci/djn075. Epub 2008 Apr 8. Erratum in: J Natl Cancer Inst. 2008 May 21;100(10):754.

PMID:
18398105
12.

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.

Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, Young RL, Wells EC, O'Sullivan MJ, Chen B, Schenken R, Johnson SR; Women's Health Initiative Investigators.

Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73.

PMID:
15863546
13.

Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.

Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J; Women's Health Initiative Investigators.

Am J Epidemiol. 2005 Sep 1;162(5):404-14. Epub 2005 Jul 20.

PMID:
16033876
14.

Postmenopausal hormone therapy: cardiovascular risks.

[No authors listed]

Prescrire Int. 2003 Apr;12(64):65-9.

PMID:
12674130
15.

Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer.

Jick SS, Hagberg KW, Kaye JA, Jick H.

Obstet Gynecol. 2009 Jan;113(1):74-80. doi: 10.1097/AOG.0b013e31818fdde4.

PMID:
19104362
16.

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.

Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE.

Am J Epidemiol. 2009 Jul 1;170(1):12-23. doi: 10.1093/aje/kwp115. Epub 2009 May 25.

17.

Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials).

Robinson JG, Wallace R, Limacher M, Ren H, Cochrane B, Wassertheil-Smoller S, Ockene JK, Blanchette PL, Ko MG.

Am J Cardiol. 2008 Sep 15;102(6):693-9. doi: 10.1016/j.amjcard.2007.12.044. Epub 2008 Jul 2.

PMID:
18773990
18.

Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.

[No authors listed]

Prescrire Int. 2004 Jun;13(71):106-9.

PMID:
15233153
19.

Postmenopausal hormone replacement therapy and venous thromboembolism.

Wu O.

Gend Med. 2005;2 Suppl A:S18-27. Review.

PMID:
16551553
20.

Estrogen and progestogen effect on venous thromboembolism in menopausal women.

Archer DF, Oger E.

Climacteric. 2012 Jun;15(3):235-40. doi: 10.3109/13697137.2012.664401. Review.

PMID:
22612609

Supplemental Content

Support Center